PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst
Seeking Alphaยท2025-08-20 19:53Company Overview - PTC Therapeutics has received FDA approval for SEPHIENCE (sepiapterin) to treat children and adults with phenylketonuria (PKU) [2] Market Position - The approval of SEPHIENCE marks a significant advancement for PTC Therapeutics in the biotech sector, enhancing its market presence [2]